The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1492
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years. ... more
     
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
Article code: 1492c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian